August 17, 2020 at 13:58 JST
BEIJING--China’s vaccine specialist CanSino Biologics Inc. has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country’s intellectual property regulator.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People’s Daily reported on Sunday.
The paper cited documents published by China’s National Intellectual Property Administration saying that the patent was issued on Aug. 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino’s Hong Kong shares rose around 14 percent in Monday’s morning session. Its Shanghai shares rose by 6.6 percent as of midday.
Historians describe the Nomonhan Incident, a little-known 1939 Japan-Soviet border conflict, as the starting point of World War II.
A mother of two sons recounts the days when she lived with the novel coronavirus.
The Asahi Shimbun aims “to achieve gender equality and empower all women and girls” through its Gender Equality Declaration.
Let’s explore the Japanese capital from the viewpoint of wheelchair users and people with disabilities with Barry Joshua Grisdale.